Paul Ryan should be kicked out of Congress: Kennedy
FBN’s Kennedy on House Speaker Paul Ryan (R-Wis.) delaying passing a spending bill which may trigger a government shutdown.
Advertisement
Recommended Stories
Morgan Stanley Predicts up to 110% Rally for These 2 ‘Strong Buy’ Stocks
Uncertainty is the word of the day, in reference to the near-term economic future. Sentiment will hinge on the inflation numbers due out next week. March’s figure rose to 3.5%, and April’s job numbers showed a marked slowing in the labor market; that combination has stoked fears of stagflation. But – corporate earnings from Q1 are beating expectations, and the stock market has taken a turn for the better with the S&P 500 closing just below 5,200 yesterday. Economic strategists are still optimist
TipRanksBillionaire Bill Gates Has 51% of His Portfolio Invested in 2 Brilliant Stocks
The Bill and Melinda Gates Foundation Trust outperformed the S&P 500 by a wide margin over the past three years, in part because of these two stocks.
Motley FoolCan I Use My RMDs to Transfer Money Into My Roth IRA?
If you're taking a required minimum distribution from an IRA, 401(k) or other tax-deferred account and don't need the money to cover living expenses, where should you stash that unneeded cash? Investors now need to start taking RMDs at age 73 or, if they were born after 1960, at age 75. Depending on the balances of […] The post Can I Use My RMDs to Transfer Money Into My Roth IRA? appeared first on SmartReads by SmartAsset.
SmartAssetHere's Exactly When Social Security Recipients Can Expect Benefit Cuts, According to the Latest Trustees Report
Social Security payments may be subject to cuts. Here's what the timing looks like.
Motley FoolTime to Pounce: 2 Historically Cheap Ultra-High-Yield Energy Stocks That Are Begging to Be Bought Right Now
These supercharged energy income stocks -- with an average yield of 9.87% -- can really fatten your pocketbook.
Motley FoolModerna’s mRNA Dreams Meet Reality With First Post-Covid Shot
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackStormy Daniels Will Return to Court in Test of Trump’s
BloombergForget Nvidia: These 3 Small-Cap Stocks Offer Up to 557% Upside, According to Select Wall Street Analysts
High-water price targets from a trio of Wall Street pundits imply three diminutive companies can skyrocket 223% to 557%.
Motley FoolCRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksStocks could tank after an ill-advised 'melt-up' if the Fed cuts rates to avoid recession
"Investors' expectation that the Fed would nip a recession in the bud by easing means that the Fed Put is back," Ed Yardeni said.
Business Insider3 Ridiculously Undervalued Stocks to Buy Hand Over Fist Right Now in May
Investing in cheap stocks brings unique risks because there is usually a reason the companies are undervalued.
Motley Fool